Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
On December 27, 2023, Iovance announced that, on December 22, 2023, the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on the Company’s IOV-LUN-202 trial, which was investigating the Iovance’s lead product candidate for the treatment of metastatic non-small cell lung cancer. Iovance advised that the FDA’s decision to place the clinical hold was “in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.”
On this news, Iovance’s stock price fell 18.67% to close at $7.23 per share on December 27, 2023.